<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment; Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment; Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2022-06-28 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment." This guidance is intended to facilitate the development of drugs and biologics for the adjuvant treatment of renal cell carcinoma and provides recommendations for the sponsor on this topic. The guidance includes recommendations regarding eligibility criteria, choice of comparator, followup imaging ...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2022-13752</p>
    <p><strong>Publication Date:</strong> 2022-06-28</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/06/28/2022-13752/renal-cell-carcinoma-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry">https://www.federalregister.gov/documents/2022/06/28/2022-13752/renal-cell-carcinoma-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-13752</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
